Consideration of liquid biomarkers for surveillance of HPV-related oropharyngeal cancer in veteran populations

Abstract

The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) will continue to rise in the United States over the next several decades. Thus, efforts to reduce treatment intensity, mitigate long-term physical and psychological sequelae of treatment, and simplify surveillance regimens for patients with HPV-related OPSCC are critical. Liquid biomarkers, namely plasma circulating tumor HPV DNA (ctDNA), have shown considerable promise for improvements in these domains by guiding personalized and adaptive treatment de-escalation paradigms and predicting disease recurrence in the survivorship period. Preliminary reports suggest an even broader impact of plasma HPV ctDNA assays for HPV-related OPSCC surveillance beyond the mere detection of cancer recurrence and metastasis. For instance, such assays may reduce the need for costly imaging studies, alleviate the financial toxicities of survivorship care, and improve care access and patient satisfaction. Currently, veterans and underserved populations are disproportionately affected by the financial burden of cancer surveillance and survivorship care. These disparities negatively impact oncologic outcomes, healthcare access, and utilization, specifically among veterans with HPV-related OPSCC. As such, we posit that HPV ctDNA monitoring may be of unique benefit and impact in the surveillance period for these patients specifically. Herein, we provide a narrative review of the current literature supporting the formal clinical evaluation of HPV ctDNA monitoring in veterans with HPV-related OPSCC.

Keywords

HPV / ctDNA / liquid biomarker / oropharynx / squamous cell carcinoma / surveillance / veterans

References

[1] Zumsteg ZS,Rosenberg PS.Global epidemiologic patterns of oropharyngeal cancer incidence trends.J Natl Cancer Inst2023;115:1544-54 PMCID:PMC10699798

[2] Zhang Y,D’Souza G.Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020-2045.JAMA Oncol2021;7:e212907 PMCID:PMC8414358

[3] Zevallos JP,Sandulache VC.National trends in oropharyngeal cancer incidence and survival within the veterans affairs health care system.Head Neck2021;43:108-15 PMCID:PMC8060873

[4] Ang KK,Wheeler R.Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med2010;363:24-35 PMCID:PMC2943767

[5] Ferris RL,Weinstein GS.Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311).J Clin Oncol2022;40:138-49

[6] Petrelli F,Trevisan F.Comparison of different treatments for HPV+ oropharyngeal carcinoma: a network meta-analysis.Eur Arch Otorhinolaryngol2023;280:963-71

[7] Lechner M,Masterson L.HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.Nat Rev Clin Oncol2022;19:306-27 PMCID:PMC8805140

[8] Masroor F,Carpenter DM,Cheung KHN.Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma.JAMA Otolaryngol Head Neck Surg2019;145:903-8 PMCID:PMC6692675

[9] Trosman SJ,Ward MC.Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.JAMA Otolaryngol Head Neck Surg2015;141:457-62

[10] Huang SH,Xu W.Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status.Int J Radiat Oncol Biol Phys2013;87:1078-85

[11] Nekhlyudov L,Siu LL.Head and neck cancer survivorship care guideline: american society of clinical oncology clinical practice guideline endorsement summary.J Oncol Pract2018;14:167-71

[12] Smith JD,Riba MB.Psychosocial issues in patients with head and neck cancer: an updated review with a focus on clinical interventions.Curr Psychiatry Rep2017;19:56

[13] De Luca P, Radici M, Camaioni A. The relationship between the upper aerodigestive tract microbiome axis and head and neck cancers: is it time to bet on it?.Eur Arch Otorhinolaryngol2023;280:4299-301

[14] Auger S,Rosenberg AJ.Recommendations for care of survivors of head and neck cancer.JAMA2022;328:1637-8

[15] National Comprehensive Cancer Network. Head and neck cancers. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [Last accessed 18 Feb 2024]

[16] Frakes JM,Demetriou SK.Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.Cancer2016;122:634-41

[17] Imbimbo M,Botta L.Surveillance of patients with head and neck cancer with an intensive clinical and radiologic follow-up.Otolaryngol Head Neck Surg2019;161:635-42

[18] Gharzai LA,Li P.Patient burden with current surveillance paradigm and factors associated with interest in altered surveillance for early stage HPV-related oropharyngeal cancer.Oncologist2021;26:676-84 PMCID:PMC8342565

[19] Kuhs KAL, Brenner JC, Holsinger FC, Rettig EM. Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review.JAMA Oncol2023;9:1716-24

[20] Hanna GJ,Jabalee J.Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance.Clin Cancer Res2023;29:4306-13 PMCID:PMC10570676

[21] Berger BM,Posner MR.Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.Clin Cancer Res2022;28:4292-301 PMCID:PMC9527497

[22] Cao Y,Brummel C.Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma.Clin Cancer Res2022;28:350-9 PMCID:PMC8785355

[23] Ferrandino RM,Kappauf C.Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus-associated oropharyngeal cancer.JAMA Otolaryngol Head Neck Surg2023;149:971-7 PMCID:PMC10331620

[24] Haring CT,Bhambhani C.Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.Oral Oncol2021;121:105332 PMCID:PMC8448944

[25] Haring CT,Brummel C.Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma.Oncotarget2021;12:1214-29 PMCID:PMC8238244

[26] Allevato MM,Brenner MJ.Tumor-derived exosomes and the role of liquid biopsy in human papillomavirus oropharyngeal squamous cell carcinoma.Cancer J2023;29:230-7 PMCID:PMC10372688

[27] Xie DX,Quon H,D’Souza G.Clinical Uncertainties of circulating tumor DNA in human papillomavirus-related oropharyngeal squamous cell carcinoma in the absence of national comprehensive cancer network guidelines.J Clin Oncol2023;41:2483-7 PMCID:PMC10489440

[28] Chera BS,Shen C.Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.J Clin Oncol2020;38:1050-8

[29] Ward MC,Walker GV,Koyfman SA.The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: a simulation.Oral Oncol2022;126:105721

[30] Dermody SM,Swiecicki PL,Tewari M.Trans-renal cell-free tumor DNA for urine-based liquid biopsy of cancer.Front Genet2022;13:879108 PMCID:PMC9091346

[31] Ferrier ST,Sadeghi N,Burnier JV.Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer.Cancer Med2023;12:15777-87 PMCID:PMC10469655

[32] Sandulache VC,Lai S.Oropharyngeal squamous cell carcinoma in the veteran population: association with traditional carcinogen exposure and poor clinical outcomes.Head Neck2015;37:1246-53 PMCID:PMC4496314

[33] Feinstein AJ,Chang E,Wang MB.Treatment outcomes in veterans with HPV-positive head and neck cancer.Am J Otolaryngol2017;38:188-92

[34] Chidambaram S,Sandulache VC,Zevallos JP.Human papillomavirus vaccination prevalence and disproportionate cancer burden among US veterans.JAMA Oncol2023;9:712-4 PMCID:PMC9982736

[35] Sandulache VC,Heasley LE.Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 field based meeting.Oral Oncol2020;102:104440 PMCID:PMC7260859

[36] Freeman VL,Arozullah AM.Determinants of mortality following a diagnosis of prostate cancer in veterans affairs and private sector health care systems.Am J Public Health2003;93:1706-12 PMCID:PMC1448038

[37] Landrum MB,Lamont EB.Survival of older patients with cancer in the veterans health administration versus fee-for-service medicare.J Clin Oncol2012;30:1072-9 PMCID:PMC3341151

[38] Henry M,Bertrand L.Prevalence and risk factors of suicidal ideation among patients with head and neck cancer: longitudinal study.Otolaryngol Head Neck Surg2018;159:843-52

[39] Chew EY,Richardson PA.Risk factors for oropharynx cancer in a cohort of HIV-infected veterans.Oral Oncol2017;68:60-6 PMCID:PMC6365160

[40] Mazul AL,Kramer J.Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV.Cancer Med2020;9:9326-35 PMCID:PMC7774719

[41] Mazul AL,Mowery YM.Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans.Cancer2022;128:3310-8 PMCID:PMC10650941

[42] Saxena K,Cyhaniuk A,Janjan N.Clinical and economic burden of HPV-related cancers in the US veteran population.J Med Econ2022;25:299-308

[43] Shay SG,Lewis MS.Characteristics of human papillomavirus-associated head and neck cancers in a veteran population.JAMA Otolaryngol Head Neck Surg2015;141:790-6

[44] Shires CB,Zafar N.Oropharyngeal squamous cell carcinoma outcomes by p16(INK4a) antigen status in a veteran population.Fed Pract2023;40:S64-7 PMCID:PMC10506496

[45] Zevallos JP,Hamblin J.Impact of race on oropharyngeal squamous cell carcinoma presentation and outcomes among veterans.Head Neck2016;38:44-50

[46] Faraji F,Voora R.Transoral surgery in HPV-positive oropharyngeal carcinoma: oncologic outcomes in the veterans affairs system.Laryngoscope2024;134:207-14 PMCID:PMC10687307

[47] Nelson TJ,Zou J.Validation of NRG oncology’s prognostic nomograms for oropharyngeal cancer in the veterans affairs database.Cancer2022;128:1948-57

[48] Richardson PA,Chen GG.Treatment patterns in veterans with laryngeal and oropharyngeal cancer and impact on survival.Laryngoscope Investig Otolaryngol2018;3:275-82 PMCID:PMC6119785

[49] Soliman O,Kemnade JO.Deployment of cisplatin in veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes.Laryngoscope Investig Otolaryngol2023;8:895-902 PMCID:PMC10446265

[50] Nobel T,Sigel K.Using veterans affairs medical center (VAMC) data to identify missed opportunities for HPV vaccination.Hum Vaccin Immunother2019;15:1878-83 PMCID:PMC6746530

[51] Sandulache VC,Sturgis EM,Sikora AG.A hidden epidemic of “Intermediate risk” oropharynx cancer.Laryngoscope Investig Otolaryngol2019;4:617-23 PMCID:PMC6929570

[52] Harbison RA,Konnick EQ.The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.JCI Insight2018;3:99327 PMCID:PMC6124437

[53] Karli K,Teresa E.Health disparities in veterans: a map of the evidence.Med Care2017;55:S9-15

[54] Skolarus TA,Shelton JB.Quality of prostate cancer care among rural men in the veterans health administration.Cancer2013;119:3629-35

[55] Gutt R,Hagan MP.Palliative radiotherapy within the veterans health administration: barriers to referral and timeliness of treatment.JCO Oncol Pract2021;17:e1913-22

[56] Ambroggi M,Del Giovane C,Cavanna L.Distance as a barrier to cancer diagnosis and treatment: review of the literature.Oncologist2015;20:1378-85 PMCID:PMC4679078

[57] De Virgilio A,Mercante G.Present and future of de-intensification strategies in the treatment of oropharyngeal carcinoma.Curr Oncol Rep2020;22:91

[58] Hargreaves S,Hurt C,Evans M.Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development.Front Oncol2019;9:936 PMCID:PMC6779788

[59] Chai RL,Barron C.The sinai robotic surgery trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial) - study protocol for a phase II non-randomized non-inferiority trial.Front Oncol2022;12:965578 PMCID:PMC9453550